好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Poor Functional Outcome Is Associated with Blood Pressure Trajectories 72 Hours After Thrombectomy: A Multicenter Analysis
Cerebrovascular Disease and Interventional Neurology
S20 - Cerebrovascular Disease: Large Vessel Occlusions and Thrombectomy (4:18 PM-4:30 PM)
005

To study the association between blood pressure trajectories after endovascular thrombectomy and functional outcome

Blood pressure (BP) is a critical and adjustable parameter after endovascular thrombectomy (EVT), and elevated BP after EVT has been associated with hemorrhagic transformation and poor functional outcome in observational studies. However, BP course after EVT is not well understood and optimal BP management after stroke remains unknown. We analyzed BP data up to 72 hours after EVT to find distinct systolic BP (SBP) trajectories and examined their associations with functional outcome.

We retrospectively assembled a cohort of 1060 patients from several centers with anterior large-vessel occlusion stroke and EVT. BP was non-invasively recorded at least hourly for the first 72 hours. Functional outcome was evaluated using the modified Rankin scale (mRS). Favorable functional outcome was defined as mRS <2. Latent variable mixture modeling was used to identify patient subgroups that have similar SBP trajectories. Analyses were adjusted for age, admission NIHSS, and recanalization status.

One thousand sixty patients (mean age 70±15, mean NIHSS 16) were used in the analysis, although more will be included in the final analysis. Five distinct SBP trajectories were observed: (1) low (17%), (2) moderate (38%), (3) moderate-to-high (21%), (4) high-to-moderate (17%), and (5) high (7%). SBP trajectory group independently predicted functional outcome at discharge (p=0.001) and 90 days (p=0.010). Patients with high and high-to-moderate SBP trajectories had a significantly higher odds of an unfavorable outcome at 90 days (adjusted OR 2.3, 95%CI 1.2 – 4.3, p=0.01 and adjusted OR 4, 95% CI 1.5-10.7, p=0.06, respectively).

Acute ischemic stroke patients demonstrate distinct SBP trajectories during the first 72 hours after EVT that differ by functional outcome. These findings may help identify potential candidates for future blood pressure control trials.

Authors/Disclosures
Sreeja Kodali
PRESENTER
Ms. Kodali has nothing to disclose.
No disclosure on file
Sumita M. Strander Ms. Strander has nothing to disclose.
No disclosure on file
Krithika Umesh Peshwe, MD (West Virginia University School of Medicine) Dr. Peshwe has nothing to disclose.
Cindy Khanh P. Nguyen (Yale University) Miss Nguyen has nothing to disclose.
Anson Wang, MD (Massachusetts General Hospital) Dr. Wang has nothing to disclose.
Alexandra Kimmel No disclosure on file
Mohammad Anadani, MD (Medical University of South Carolina) Dr. Anadani has nothing to disclose.
No disclosure on file
Ka-Ho Wong (U of U Neurology Clinic) The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Adam De Havenon, MD, FAAN (Yale University) Dr. De Havenon has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. De Havenon has stock in Certus. Dr. De Havenon has stock in TitinKM. The institution of Dr. De Havenon has received research support from NIH/NINDS. Dr. De Havenon has received publishing royalties from a publication relating to health care.
No disclosure on file
No disclosure on file
Santiago Ortega Gutierrez, MD (University of Iowa) Dr. Ortega Gutierrez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for stryker. Dr. Ortega Gutierrez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for medtronic. Dr. Ortega Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. The institution of Dr. Ortega Gutierrez has received research support from stryker. The institution of Dr. Ortega Gutierrez has received research support from Medtronic. The institution of Dr. Ortega Gutierrez has received research support from Methinks. The institution of Dr. Ortega Gutierrez has received research support from NIH. The institution of Dr. Ortega Gutierrez has received research support from PCORI.
Eva Mistry No disclosure on file
No disclosure on file
Eva Mistry No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Fnu Abhi Pandhi, MD (UTHSC Dept of Neurology) No disclosure on file
Nitin Goyal, MD (University of Tennessee HSC) No disclosure on file
No disclosure on file
Fabio Nascimento, MD (Washington University Medical School) Dr. Nascimento has received publishing royalties from a publication relating to health care. Dr. Nascimento has a non-compensated relationship as a Editorial Team Member with Neurology RFS that is relevant to AAN interests or activities. Dr. Nascimento has a non-compensated relationship as a Production Team with Neurology Podcast that is relevant to AAN interests or activities.
No disclosure on file
No disclosure on file
No disclosure on file
Joontae Kim, MD, PhD (Chonnam National University Hospital) Dr. KIM has nothing to disclose.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care) Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
Nils Petersen, MD (Yale University) The institution of Dr. Petersen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Silkroad Medical. Dr. Petersen has received research support from NIH.